BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Center for RNA Biomedicine - ECPv6.15.20//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Center for RNA Biomedicine
X-ORIGINAL-URL:https://rna.umich.edu
X-WR-CALDESC:Events for Center for RNA Biomedicine
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:America/Detroit
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20210314T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20211107T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20220313T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20221106T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20230312T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20231105T060000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=America/Detroit:20220516T160000
DTEND;TZID=America/Detroit:20220516T170000
DTSTAMP:20260501T153607
CREATED:20220218T163352Z
LAST-MODIFIED:20220506T161447Z
UID:10130-1652716800-1652720400@rna.umich.edu
SUMMARY:RNA Innovation Seminar: Daniel O’Reilly
DESCRIPTION:“An Academic Approach to Oligonucleotide Therapeutics”\nDaniel O’Reilly Ph.D.\, MRSC\nPost-Doctoral Associate\nKhvorova Lab\nRNA Therapeutics Institute\nUniversity of Massachusetts Medical School \nFlyer in PDF \n  \nHYBRID SEMINAR:\nIn-person: BSRC\, ABC seminar rooms\nZoom: https://umich.zoom.us/webinar/register/WN_dM1a1aKVTM2KfwiieutOWg \nKeywords: Oligonucleotides\, Chemical Modifications\, RNA\, Huntington’s Disease \nAbstract: Nucleic acids (NA) are becoming the third major pillar of therapeutic modalities on par with small molecules and biologics. The diversity of NA molecular mechanisms\, ranging from vaccines\, antisense\, short interfering RNA (siRNAs)\, and guide RNA for CRISPR gene editing systems\, enable impact on most aspects of cellular biology and thus human medicine. The foundation behind the recent oligonucleotides’ clinical success is fundamental chemical innovations in RNA stability\, delivery\, and synthesis.\nOligonucleotides are informational drugs; thus\, if chemical architectures supporting safe and efficient delivery to the tissue of interest are achieved\, they can be easily reprogrammed to modulate any gene expression on demand\, creating an opportunity for academic institutions to drive therapeutic innovation. However\, the process is limited by access to oligonucleotide chemistry and synthetic expertise.\nIn the first half of the talk\, I will share the experience of building and running Nucleic Acid Chemistry Center in a context of a large academic institution. The NACC provides access to therapeutic quality screening leads and large manufacturing of preclinical compounds for the academic community. The impact of the NACC and chemical innovation will be discussed in the context of two significant projects. First\, I will discuss the systematic structure-activity relationship study of chemical modifications to modulate RISC loading and cleavage. Screening 1200 siRNA variants allow for defining the chemical and thermodynamic rules for RISC assembly.
URL:https://rna.umich.edu/events/daniel-oreilly/
CATEGORIES:Seminar
END:VEVENT
END:VCALENDAR